The ASN’s Diabetic Kidney Disease Collaborative (DKD-C) has organized a series of three virtual roundtable discussions on the management of diabetic kidney disease to occur this summer and fall. Registration is free and open to all ASN members and partner organizations.
The first session, “Management of Diabetes and Kidney Disease Through COVID-19,” will be held on Tuesday, Aug. 18, from noon to 1:30 p.m. EDT. The discussion will detail the care needs and patient experience managing diabetes and kidney disease during the COVID-19 pandemic, outline frequent patient concerns, and provide strategies for maintaining health. The conversation will touch on population susceptibility to diabetes, a personal journey of COVID-19 and DKD management, patient access to new therapies, and coordinating DKD care.
The second session, “Goal-Directed Medical Therapies for Patients with Diabetic Kidney Disease,” will be held on Tuesday, Sept. 29, from noon to1:30 p.m. EDT. During this event, leading experts in the care of individuals with diabetic kidney disease will describe the new standard of care for DKD, discuss the clinical indications for SGLT2 (sodium-glucose cotransporter-2) inhibitors, and consider payment issues associated with new therapies. The session will address topics such as paying for new therapies and will conclude with a roundtable discussion.
“New Approaches to Transform Outcomes for Kidney Disease and Heart Disease in Diabetes,” is the topic of the final webinar, which will be held Thursday, Dec. 10, from 4 p.m. to 5:30 p.m. EST. Clinical experts in this session will review the latest guidelines for both kidney and heart disease, discussing the evolving landscape for diabetic kidney disease as well as the most recent trials and promising therapies. A roundtable of experts from nephrology, cardiology and endocrinology will note the implications for diabetes, kidney, and heart disease treatment as we head into 2021.
The events are sponsored by Bayer, AstraZeneca, Janssen, Eli Lilly, and Baxter International.
“After decades of waiting, we have entered an exciting new era where nephrologists have powerful new treatments to dramatically slow and even halt the progression of kidney disease in patients,” said Susan Quaggin, MD, FASN, chair of the DKD-C Task Force. “The DKD-C Task Force has a goal to make sure these treatments reach the patients who need them.”
The DKD-C was launched by ASN in July 2019 in response to the recent development of new therapies for people with diabetic kidney disease. The collaborative works to increase coordination among primary care physicians, nephrologists, and other specialists to deliver appropriate therapies to people living with DKD. It also aims to provide educational information to help nephrologists and other health professionals provide high-quality care to people with DKD and to address legislative, regulatory, and policy issues that affect the ability of nephrologists and other health professionals to provide high-quality care to people with DKD. DKD remains one of the most common and serious complications of type 2 diabetes.
